ZA201600312B - Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders - Google Patents

Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Info

Publication number
ZA201600312B
ZA201600312B ZA2016/00312A ZA201600312A ZA201600312B ZA 201600312 B ZA201600312 B ZA 201600312B ZA 2016/00312 A ZA2016/00312 A ZA 2016/00312A ZA 201600312 A ZA201600312 A ZA 201600312A ZA 201600312 B ZA201600312 B ZA 201600312B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
treatment
therapeutic agents
movement disorders
hyperkinetic movement
Prior art date
Application number
ZA2016/00312A
Other languages
English (en)
Inventor
Batalla Núria Gavaldà
Boronat Raúl Insa
Bolaño Núria Reig
Original Assignee
Som Innovation Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201600312(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech S L filed Critical Som Innovation Biotech S L
Publication of ZA201600312B publication Critical patent/ZA201600312B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2016/00312A 2013-06-19 2016-01-14 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders ZA201600312B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
ZA201600312B true ZA201600312B (en) 2022-12-21

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/00312A ZA201600312B (en) 2013-06-19 2016-01-14 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Country Status (19)

Country Link
US (2) US9789072B2 (enExample)
EP (1) EP3010543B1 (enExample)
JP (1) JP6476174B2 (enExample)
KR (1) KR102254542B1 (enExample)
CN (1) CN105658238B (enExample)
AU (1) AU2014283319B2 (enExample)
BR (1) BR112015031835B1 (enExample)
CA (1) CA2915811C (enExample)
CL (1) CL2015003679A1 (enExample)
DK (1) DK3010543T3 (enExample)
ES (1) ES3053333T3 (enExample)
IL (1) IL243192B (enExample)
MX (1) MX366353B (enExample)
PL (1) PL3010543T3 (enExample)
PT (1) PT3010543T (enExample)
RU (1) RU2685502C2 (enExample)
SG (1) SG11201510451RA (enExample)
WO (1) WO2014202646A1 (enExample)
ZA (1) ZA201600312B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
CA3076000A1 (en) * 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
ES2569483T3 (es) 2007-06-21 2016-05-11 Amgen Inc. Métodos para sintetizar cinacalcet y sales del mismo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US8197858B2 (en) 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
RS53227B (sr) * 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань

Also Published As

Publication number Publication date
MX366353B (es) 2019-07-05
EP3010543A1 (en) 2016-04-27
NZ715951A (en) 2021-03-26
PT3010543T (pt) 2025-11-28
US9789072B2 (en) 2017-10-17
PL3010543T3 (pl) 2026-01-19
CL2015003679A1 (es) 2016-09-02
CA2915811C (en) 2021-08-31
SG11201510451RA (en) 2016-01-28
EP3010543B1 (en) 2025-11-05
US20180042869A1 (en) 2018-02-15
RU2685502C2 (ru) 2019-04-19
CN105658238B (zh) 2019-07-12
JP6476174B2 (ja) 2019-02-27
BR112015031835B1 (pt) 2022-12-13
KR102254542B1 (ko) 2021-05-24
RU2016101152A (ru) 2017-07-24
BR112015031835A2 (pt) 2017-07-25
AU2014283319B2 (en) 2019-07-25
JP2016522235A (ja) 2016-07-28
MX2015018040A (es) 2016-08-03
IL243192A0 (en) 2016-02-29
WO2014202646A1 (en) 2014-12-24
IL243192B (en) 2019-12-31
KR20160055121A (ko) 2016-05-17
AU2014283319A1 (en) 2016-02-11
BR112015031835A8 (pt) 2019-12-31
CA2915811A1 (en) 2014-12-24
US20160158167A1 (en) 2016-06-09
HK1223014A1 (en) 2017-07-21
DK3010543T3 (da) 2025-12-01
CN105658238A (zh) 2016-06-08
ES3053333T3 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
ZA201507155B (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
IL240169A0 (en) Pyrimidine compositions for use in the treatment of diseases affected by ikke or tbk1 mechanisms
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
GB2538923B (en) A therapeutic agent for use in the treatment of infections
SI2956471T1 (sl) Sestava za zaviralca il-1beta in njegova uporaba
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
ZA201508050B (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
IL246855A0 (en) Materials for use in the treatment of retinitis
SG11201510451RA (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease